Sutro Biopharma STRO Financing Component Associated With Program Fees
Financing Component Associated With Program Fees at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept stro:FinancingComponentAssociatedWithProgramFees.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's financing component associated with program fees.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's financing component associated with program fees?
- Sutro Biopharma (STRO) reported financing component associated with program fees of $911K in Q1 2026.
- How has Sutro Biopharma's financing component associated with program fees changed year-over-year?
- Sutro Biopharma's financing component associated with program fees decreased by 22.5% year-over-year, from $1.18M to $911K.
- What is the long-term trend for Sutro Biopharma's financing component associated with program fees?
- Over 2 years (2023 to 2025), Sutro Biopharma's financing component associated with program fees has grown at a -41.1% compound annual growth rate (CAGR), from $9.84M to $3.41M.
- What does financing component associated with program fees mean?
- This captures the portion of revenue or payments from collaborative agreements that is classified as a financing component rather than operating revenue. It reflects the interest-like element embedded in long-term contracts where payments are received in advance of performance obligations. Distinguishing this component helps investors accurately assess the company's core operational revenue versus its financing activities.